Literature DB >> 29775084

Health state utilities in patients with advanced non-small-cell lung cancer in China.

Yunjie Shen1, Bin Wu2, Xiaohui Wang1, Jun Zhu1.   

Abstract

AIM: Non-small-cell lung cancer (NSCLC) is a leading global health threat that impairs patient health outcomes. Health state utilities are fundamental values in economic evaluation and significantly vary across countries. Given the scarce data on the Chinese population, the current study measured utility values in the Chinese patients with NSCLC.
METHODS: This study was conducted as a cross-sectional survey of patients with advanced NSCLC at the Shanghai Chest Hospital. Utility values were assessed using the EuroQol five-dimension (EQ-5D) instrument and scored based on the Chinese-specific value algorithm. Predictors of utility values were examined using a subgroup analysis and a multiple regression model.
RESULTS: The mean EQ-5D utility value of recruited patients was 0.814. The regression analysis revealed that tumor stage, treatment regimen and line of therapy were the potential predictors of utility values.
CONCLUSION: This study provides the Chinese-specific health utility data for advanced NSCLC using the EQ-5D.

Entities:  

Keywords:  China; EuroQol-5D; economic evaluation; non-small-cell lung cancer; utility

Mesh:

Year:  2018        PMID: 29775084     DOI: 10.2217/cer-2017-0069

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  13 in total

1.  Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China.

Authors:  Haijing Guan; Chunping Wang; Chen Chen; Sheng Han; Zhigang Zhao
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

2.  Coping, mood and health-related quality of life: a cross-sectional study in Chinese patients with advanced lung cancer.

Authors:  Yaping He; Hong Jian; Meiqiong Yan; Jingfen Zhu; Guohong Li; Vivian W Q Lou; Jieling Chen
Journal:  BMJ Open       Date:  2019-05-05       Impact factor: 2.692

3.  First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China.

Authors:  Ling-Yu Li; Hong Wang; Xiao Chen; Wen-Qian Li; Jiu-Wei Cui
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

4.  PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China.

Authors:  Qiao Liu; Xia Luo; Zhen Zhou; Liubao Peng; Lidan Yi; Xiaomin Wan; Chongqing Tan; Xiaohui Zeng
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

5.  Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China.

Authors:  Liu Liu; Yan Wei; Yue Teng; Juntao Yan; Fuming Li; Yingyao Chen
Journal:  Patient Prefer Adherence       Date:  2022-02-04       Impact factor: 2.711

6.  Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer.

Authors:  Xia Luo; Qiao Liu; Zhen Zhou; Lidan Yi; Liubao Peng; Xiaomin Wan; Xiaohui Zeng; Chongqing Tan; Sini Li
Journal:  Front Pharmacol       Date:  2022-04-19       Impact factor: 5.988

7.  Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.

Authors:  Taihang Shao; Yinan Ren; Mingye Zhao; Wenxi Tang
Journal:  Front Public Health       Date:  2022-08-15

8.  Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China.

Authors:  Qian Xie; Hanrui Zheng; Na Su; Qiu Li
Journal:  BMJ Open       Date:  2022-08-05       Impact factor: 3.006

9.  Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.

Authors:  Guiyuan Xiang; Lingna Gu; Xuan Chen; Fan Wang; Bohua Chen; Jie Zhao; Yun Lu; Feng Chang; Yumei Zhu
Journal:  Front Public Health       Date:  2021-12-10

10.  Health state utility values by cancer stage: a systematic literature review.

Authors:  Mir-Masoud Pourrahmat; Ashley Kim; Anuraag R Kansal; Marg Hux; Divya Pushkarna; Mir Sohail Fazeli; Karen C Chung
Journal:  Eur J Health Econ       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.